



October 2, 2017

Press Release

Astellas Pharma Inc.
TOA EIYO LTD.

Astellas and TOA EIYO Announce Co-promotion Agreement for Kiklin[®] Capsules 250mg and Kiklin[®] Granules 86.2%

Astellas Pharm Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and TOA EIYO LTD. (President: Atsuo Takahashi, “TOA EIYO”) announced that the companies have entered into a co-promotion agreement of Astellas’ products for the treatment of hyperphosphatemia, Kiklin[®] Capsules 250mg (generic name: Bixalomer, “Kiklin[®] Capsules”) and Kiklin[®] Granules 86.2% (“Kiklin[®] Granules”), in Japan, starting from Oct, 2017.

While Astellas and Sanwa Kagaku Kenkyusho Co., Ltd. have co-promoted Kiklin[®] Capsules and Kiklin[®] Granules through the Astellas distribution, TOA EIYO will additionally conduct the promotion under the terms of this agreement. This partnership will enable the enforcement and enhancement of activities providing Kiklin[®] Capsules and Kiklin[®] Granules product information leading to more contribution to the hyperphosphatemia treatment for patients suffering from chronic kidney disease (“CKD”).

Bixalomer was discovered by Ilypsa, Inc., now a wholly-owned subsidiary of Amgen Inc. In April 2006, Astellas and Ilypsa, Inc. entered into a license agreement that grants Astellas exclusive rights to develop and commercialize bixalomer in Japan and then, Astellas conducted the development of bixalomer.

In June 2012, Astellas launched Kiklin[®] Capsules for the indication of hyperphosphatemia in patients on dialysis with CKD in Japan. Astellas also received an approval for a supplemental new drug application of Kiklin[®] Capsules for the treatment of CKD patients not on dialysis with hyperphosphatemia in February 2016. In December 2016, Astellas launched Kiklin[®] Granules as an additional formulation of Kiklin[®] Capsules in Japan.

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.

About TOA EIYO

TOA EIYO LTD., based in Tokyo, Japan, is a company dedicated to contributing to the health of people through unique medicines primarily in the cardiovascular fields. TOA EIYO aims to be a specialized pharmaceutical company that is truly indispensable to the medical front lines via our research and development of new medicines and value-added generic drugs in the cardiovascular fields including ischemic heart disease, arrhythmia and heart failure, and other related fields.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

【Contacts for inquiries or additional information】

Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201
<http://www.astellas.com/en/>

TOA EIYO LTD.
Corporate Strategy & Planning Section
TEL: +81-3-5542-8807
<http://www.toaeiyo.co.jp/english/>